Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .
Duloxetine for premenstrual dysphoric disorder: a pilot study
Objective : Premenstrual dysphoric disorder ( PMDD ) is a complex clinical syndrome that is notoriously difficult to treat . The purpose of the present study was to provide preliminary data on the effectiveness of duloxetine in PMDD . Research design and methods : Fifty-five women with PMDD were treated with a 60 mg/day dosage of duloxetine for two menstrual cycles . Responses were assessed at first and second treatment cycle . Main outcome measures : Outcome measures included a visual analogue scale , the Zung Self-rating Scale for Depression , the Hamilton Depression Rating Scale , the Hamilton Anxiety Rating Scale and the Clinical Global Impressions Scale . Results : Fifty patients completed the trial . All had significant improvement of depression and anxiety and response , defined as a 50 % decrease in daily symptom scores , occurred in 39 ( 78 % ) patients . The effects of active treatment were marked by the first active cycle of menstruation . Conclusions : Duloxetine 60 mg/day was effective in reducing PMDD symptoms and generally well tolerated . Limitations of the study were open-label design and lack of placebo control . However , the results appeared to be strong and consistent across measures . Adverse events ( nausea , insomnia , poor appetite ) were low . Further studies are needed to confirm these results
Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .